Sep 13, 2021 6:00am EDT Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold
Aug 16, 2021 7:00am EDT Matinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections
Aug 10, 2021 6:31am EDT Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
Jul 27, 2021 7:00am EDT Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021
May 10, 2021 6:30am EDT Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
Apr 28, 2021 7:30am EDT Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
Apr 27, 2021 7:30am EDT Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021
